BACKGROUND: The phase III EXTREME and CRYSTAL studies demonstrated that the
addition of cetuximab to chemotherapy significantly improved survival in the first-line …

Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a
monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to …

Abstract Background The phase III EXTREME study demonstrated that combining cetuximab
with platinum/5-fluorouracil (5-FU) significantly improved overall survival in the first-line …

Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …

The epidermal growth factor receptor (EGFR) has been shown to be a promising therapeutic
target in head and neck cancer. Cetuximab, a monoclonal antibody against EGFR, has been …

The epidermal growth factor receptor‐(EGFR‐) directed antibody, cetuximab, was FDA‐
approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in …

The anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibody cetuximab
specifically binds to the EGFR with high affinity, blocking growth-factor binding, receptor …

The epidermal growth factor (EGF) and its receptor were discovered nearly 40 years ago.
Over the past decade interruption of this pathway has been exploited in the treatment of …

Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the …

New agents and treatment strategies that can be safely and effectively integrated into current
treatment paradigms for head and neck squamous cell carcinoma (HNSCC) are urgently …